Ocugen, Inc. is a fully integrated biotech company based in Malvern, PA, dedicated to discovering, developing, and commercializing innovative gene and cell therapies as well as vaccines. With a patient-centric approach, Ocugen aims to improve global health and provide hope for patients worldwide. Their breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases, while their vaccine research focuses on combating COVID-19. Additionally, Ocugen is working on regenerative cell therapies to address orthopedic diseases with limited treatment options.
Driven by a commitment to courageous innovation, Ocugen is pushing the boundaries of medicine to find new solutions for unmet medical needs. Their mucosal vaccine, COVAXIN, utilizes a traditional vaccine platform with a novel adjuvant, while their modifier gene therapy platform offers a new approach to treating inherited retinal diseases and blindness. Through their regenerative cell therapy platform, Ocugen aims to provide effective treatments for serious conditions like articular cartilage lesions. With a dedicated team of professionals, Ocugen is determined to transform lives and offer hope to patients facing challenging health conditions.
Generated from the website